Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)

    Summary
    EudraCT number
    2020-000571-20
    Trial protocol
    GB   DE   DK   HU   NL   PL   CZ  
    Global end of trial date
    13 Nov 2023

    Results information
    Results version number
    v2(current)
    This version publication date
    24 Jan 2025
    First version publication date
    28 Nov 2024
    Other versions
    v1
    Version creation reason

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    D9180C00002
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04631016
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    MedImmune, LLC
    Sponsor organisation address
    One MedImmune Way, Gaithersburg, Maryland, United States, 20878
    Public contact
    Global Clinical Lead, AstraZeneca Clinical Study Information Center, +1 8772409479, information.center@astrazeneca.com
    Scientific contact
    Global Clinical Lead, AstraZeneca Clinical Study Information Center, +1 8772409479, information.center@astrazeneca.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    24 Jan 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    13 Nov 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study is to assess the effects of MEDI3506 compared with placebo on pulmonary function in participants with chronic obstructive pulmonary disease (COPD) and chronic bronchitis.
    Protection of trial subjects
    The conduct of this clinical study met all local and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonization guideline: Good Clinical Practice, and applicable regulatory requirements. Participants signed an informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.
    Background therapy
    Participants who have a documented stable regimen of dual therapy or triple therapy for >= 3 months prior to enrollment; there should have been no change in treatment after the previous exacerbation prior to entering into the study. Where dual therapy consists of inhaled corticosteroids (ICS) + long-acting beta 2 agonist (LABA) or LABA + long-acting muscarinic receptor antagonist (LAMA), and triple therapy consists of ICS + LABA + LAMA. Both dual and triple therapy may be in the form of separate inhalers of fixed dose combination inhalers but may not be in nebulized form.
    Evidence for comparator
    Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD). In the Phase 2 study, primary endpoint exacerbation rate was not met. Subgroup analysis showed that itepekimab reduced exacerbation rate and improved lung function in former smokers with COPD (Rabe et al. Lancet Respir Med 2021;9: 1288–98). Astegolimab, a selective ST2 IgG2 monoclonal antibody did not significantly reduce exacerbation rate in the Phase 2 study, but did improve health status compared with placebo (Yousuf et al. Lancet Respir Med 2022; 10: 469–77).
    Actual start date of recruitment
    14 Dec 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 5
    Country: Number of subjects enrolled
    Canada: 6
    Country: Number of subjects enrolled
    Czechia: 1
    Country: Number of subjects enrolled
    Denmark: 12
    Country: Number of subjects enrolled
    Germany: 14
    Country: Number of subjects enrolled
    Hungary: 32
    Country: Number of subjects enrolled
    Israel: 5
    Country: Number of subjects enrolled
    Poland: 26
    Country: Number of subjects enrolled
    South Africa: 5
    Country: Number of subjects enrolled
    Spain: 16
    Country: Number of subjects enrolled
    United Kingdom: 9
    Country: Number of subjects enrolled
    United States: 4
    Worldwide total number of subjects
    135
    EEA total number of subjects
    101
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    62
    From 65 to 84 years
    73
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 47 centers in 12 countries (Australia, Canada, Czech Republic, Denmark, Germany, United Kingdom, Hungary, Israel, Poland, South Africa, Spain, and USA).

    Pre-assignment
    Screening details
    A total of 137 participants were randomized, of which 135 participants received at least one dose of study drug.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Investigator, Monitor, Assessor, Subject

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Tozorakimab
    Arm description
    Participants received 7 doses of subcutaneous (SC) tozorakimab Dose Level 1 injection once every 4 weeks (Q4W).
    Arm type
    Experimental

    Investigational medicinal product name
    Tozorakimab
    Investigational medicinal product code
    MEDI3506
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Seven doses of SC tozorakimab Dose Level 1 injection once Q4W.

    Arm title
    Placebo
    Arm description
    Participants received 7 doses of SC placebo injection matched to tozorakimab once Q4W.
    Arm type
    Experimental

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Seven doses of SC placebo injection matched to tozorakimab once Q4W.

    Number of subjects in period 1
    Tozorakimab Placebo
    Started
    67
    68
    Completed
    58
    63
    Not completed
    9
    5
         Consent withdrawn by subject
    5
    4
         Failure to meet randomization criteria
    -
    1
         Adverse event, non-fatal
    3
    -
         Reason unspecified
    1
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Tozorakimab
    Reporting group description
    Participants received 7 doses of subcutaneous (SC) tozorakimab Dose Level 1 injection once every 4 weeks (Q4W).

    Reporting group title
    Placebo
    Reporting group description
    Participants received 7 doses of SC placebo injection matched to tozorakimab once Q4W.

    Reporting group values
    Tozorakimab Placebo Total
    Number of subjects
    67 68 135
    Age categorical
    Units: Participants
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    29 33 62
        From 65-84 years
    38 35 73
        85 years and over
    0 0 0
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    64.5 ( 8.3 ) 64.3 ( 6.1 ) -
    Sex: Female, Male
    Units: Participants
        Female
    26 27 53
        Male
    41 41 82
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0
        Asian
    0 1 1
        Native Hawaiian or Other Pacific Islander
    0 0 0
        Black or African American
    1 1 2
        White
    64 65 129
        More than one race
    0 0 0
        Unknown or Not Reported
    2 1 3
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    1 2 3
        Not Hispanic or Latino
    66 66 132
        Unknown or Not Reported
    0 0 0

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Tozorakimab
    Reporting group description
    Participants received 7 doses of subcutaneous (SC) tozorakimab Dose Level 1 injection once every 4 weeks (Q4W).

    Reporting group title
    Placebo
    Reporting group description
    Participants received 7 doses of SC placebo injection matched to tozorakimab once Q4W.

    Primary: Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic

    Close Top of page
    End point title
    Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic
    End point description
    The mean change from baseline in Pre-BD FEV1 at Week 12 (tozorakimab – placebo) estimated using a repeated measures mixed effects analysis of covariance measures was estimated. Data available from all visits up to and including Week 12, irrespective of whether the participant discontinued study drug or received reliever therapy was considered. FEV1 was measured by spirometry at clinic. Intent-to-treat (ITT) population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Primary
    End point timeframe
    Baseline (Day -35 to Day -28) through Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Litre
        least squares mean (standard error)
    0.019 ( 0.026 )
    -0.005 ( 0.025 )
    Statistical analysis title
    Statistical Analysis 1
    Comparison groups
    Tozorakimab v Placebo
    Number of subjects included in analysis
    135
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    = 0.216
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    0.024
    Confidence interval
         level
    80%
         sides
    2-sided
         lower limit
    -0.015
         upper limit
    0.063

    Secondary: Serum Tozorakimab Concentration

    Close Top of page
    End point title
    Serum Tozorakimab Concentration [1]
    End point description
    Serum concentration of tozorakimab collected over time are reported. The lower limit of quantification (LLOQ) for tozorakimab was considered to be 10 μg/L. Pharmacokinetic (PK) evaluable population included participants who received at least 1 dose of tozorakimab and had at least 1 detectable post-treatment sample available. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who had adequate PK sample available at the specified time point.
    End point type
    Secondary
    End point timeframe
    Post-dose at Study Weeks 2, 4, 12, 20, 24, 28, 32, and 36
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only those baseline period arms for which analysis was planned were reported in the end point.
    End point values
    Tozorakimab
    Number of subjects analysed
    65
    Units: μg/L
    arithmetic mean (standard deviation)
        Week 2 (n=64)
    24604.70 ( 43934.55 )
        Week 4 (n=65)
    8041.59 ( 22355.66 )
        Week 12 (n=63)
    7548.78 ( 6416.68 )
        Week 20 (n=62)
    10789.81 ( 31903.70 )
        Week 24 (n=58)
    6410.05 ( 4123.46 )
        Week 28 (n=58)
    7289.36 ( 5331.35 )
        Week 32 (n=57)
    1483.19 ( 1779.88 )
        Week 36 (n=58)
    420.13 ( 701.12 )
    No statistical analyses for this end point

    Secondary: Number of Participants With Positive Anti-drug Antibodies (ADA) to Tozorakimab

    Close Top of page
    End point title
    Number of Participants With Positive Anti-drug Antibodies (ADA) to Tozorakimab
    End point description
    Number of participants with positive ADA to tozorakimab are reported. Treatment-induced ADA positive is defined as ADA negative at baseline and positive at post-baseline assessment. Treatment-boosted ADA positive is defined as ADA positive at baseline and boosted (>= 4 fold) the pre-existing titre during the study period. Persistent positive is defined as ADA negative at baseline and positive at >= 2 post-baseline assessments (with >= 16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as ADA negative at baseline and at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who had at least one post-baseline ADA assessment.
    End point type
    Secondary
    End point timeframe
    Pre-dose at Study Weeks 0 (baseline) and post-dose at Study Weeks 2, 4, 12, 20, 24, 28, 32, and 36
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    66
    65
    Units: Participants
        Treatment-induced ADA
    1
    0
        Treatment-boosted ADA
    0
    0
        Persistently positive ADA
    0
    0
        Transiently positive ADA
    1
    0
    No statistical analyses for this end point

    Secondary: Number of Participants Experiencing First Chronic Obstructive Pulmonary Disease Composite Exacerbations (COPDCompEx) Event

    Close Top of page
    End point title
    Number of Participants Experiencing First Chronic Obstructive Pulmonary Disease Composite Exacerbations (COPDCompEx) Event
    End point description
    The COPDCompEx combines exacerbations with events defined from participant e-Diaries and peak expiratory flow (PEF). COPDCompEx defined exacerbations included episodes leading to one or more of the following: hospitalization, emergency room visit, treatment with systemic corticosteroids (injected and/or oral), or treatment with antibiotics. Diary COPDCompEx events are defined by threshold and slope criteria being met for >= 2 consecutive days using the following diary and home spirometry variables: overall symptom rating, night-time awakenings due to symptoms, reliever medication use, PEF. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -35 to Day -28) through Week 28
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Participants
    28
    36
    Statistical analysis title
    Hazard ratio
    Comparison groups
    Tozorakimab v Placebo
    Number of subjects included in analysis
    135
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.186
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.79
    Confidence interval
         level
    80%
         sides
    2-sided
         lower limit
    0.57
         upper limit
    1.11

    Secondary: Change From Baseline to Week 12 in 4-weekly Mean Evaluating Respiratory Symptoms of COPD (E-RS:COPD) Total Score

    Close Top of page
    End point title
    Change From Baseline to Week 12 in 4-weekly Mean Evaluating Respiratory Symptoms of COPD (E-RS:COPD) Total Score
    End point description
    Change from baseline to Week 12 in 4-weekly mean E-RS:COPD total score is reported. The E-RS™:COPD is an 11-item electronic patient reported outcome (ePRO) questionnaires developed to evaluate the severity of respiratory symptoms of COPD including breathlessness (5 items; score range: 0 to 17), cough and sputum (3 items; score range: 0 to 11), and chest symptoms (3 items; score range: 0 to 12). The ePRO was completed every day at home and at site visits. Summation of E-RS:COPD item responses produced a total score ranging from 0 to 40, with higher scores indicating greater severity. The 4-weekly mean will be calculated as the sum of all non-missing daily scores over the 28-day evaluation period, divided by the number of non-missing daily scores. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Baseline (from evening of Study Day -14 to the morning of Study Day 1) through Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Units on a scale
        least squares mean (standard error)
    -6.09 ( 1.004 )
    -6.06 ( 0.962 )
    No statistical analyses for this end point

    Secondary: Change From Baseline to Week 12 in Mean Breathlessness, Cough and Sputum Scale (BCSS) Score (Over the Previous 4 Weeks)

    Close Top of page
    End point title
    Change From Baseline to Week 12 in Mean Breathlessness, Cough and Sputum Scale (BCSS) Score (Over the Previous 4 Weeks)
    End point description
    Change from baseline to Week 12 in mean BCSS score (over the previous 4 weeks) is reported. The BCSS was a 3-item daily diary that assesses the severity of the 3 symptoms: breathlessness, sputum, and cough, each on a 5-point Likert scale ranging from 0 (no symptoms) to 4 (severe symptoms). Item scores were summed to yield a total score ranging from 0 to 12; wherein higher total score indicated more severe symptoms. The BCSS was captured each evening via eDiary. The 4-weekly mean BCSS score was calculated as the sum of all non-missing daily scores over the 28-dayevaluation period, divided by the number of non-missing daily scores. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Baseline (from evening of Study Day -14 to the morning of Study Day 1) through Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Units on a scale
        least squares mean (standard error)
    -2.18 ( 0.313 )
    -2.18 ( 0.298 )
    No statistical analyses for this end point

    Secondary: Percentage of Participants With a Decrease in SGRQ Total score of >= 4 Points From Baseline to Week 12

    Close Top of page
    End point title
    Percentage of Participants With a Decrease in SGRQ Total score of >= 4 Points From Baseline to Week 12
    End point description
    SGRQ: 50-item ePRO instrument developed to measure health status of participants with airway obstruction diseases and is divided into 2 parts. Part 1: 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; Part 2: 42 items related to daily activity and psychosocial impacts of participant’s respiratory condition. The SGRQ yielded total score and 3 domain scores (symptoms, activity, impacts). Total score indicated impact of disease on overall health status, which was expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Domain scores range from 0 to 100, higher scores indicative of greater impairment. A change of 4 units/points is associated with a minimum clinically important difference. ITT population: participants who received any study drug and were analyzed according to treatment they actually received. Number of participants analyzed: participants evaluable at Week 12.
    End point type
    Secondary
    End point timeframe
    Baseline (from evening of Study Day -14 to the morning of Study Day 1) through Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    62
    65
    Units: Percentage of Participants
        number (not applicable)
    61.3
    61.5
    No statistical analyses for this end point

    Secondary: Change From Baseline to Week 12 in Cough Visual Analogue Scale (VAS) Score

    Close Top of page
    End point title
    Change From Baseline to Week 12 in Cough Visual Analogue Scale (VAS) Score
    End point description
    Change from baseline to Week 12 in cough VAS score is reported. Participants were asked to complete a cough severity VAS (100 mm linear scale marked with a horizontal line by the participant, with 0 mm representing ‘‘no cough’’ and 100 mm representing “worst cough”) that measured subjective assessment by the participant of the prior 24 hrs for severity of cough symptoms. It was completed each evening in the eDiary. The 4-weekly mean cough VAS score was calculated as the sum of all non-missing daily scores over the 28-day evaluation period, divided by the number of non-missing daily scores. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Baseline (from evening of Study Day -14 to the morning of Study Day 1) through Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: mm
        least squares mean (standard error)
    -17.21 ( 3.639 )
    -17.70 ( 3.483 )
    No statistical analyses for this end point

    Secondary: Change From Baseline to Week 12 in Saint George’s Respiratory Questionnaire (SGRQ) Total Score

    Close Top of page
    End point title
    Change From Baseline to Week 12 in Saint George’s Respiratory Questionnaire (SGRQ) Total Score
    End point description
    The SGRQ was a 50-item ePRO instrument developed to measure health status of participants with airway obstruction diseases and is divided into 2 parts. Part 1: 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; Part 2: 42 items related to daily activity and psychosocial impacts of participant’s respiratory condition. The SGRQ yielded a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicated impact of disease on overall health status, which was expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. The domain scores range from 0 to 100, with higher scores indicative of greater impairment. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 12.
    End point type
    Secondary
    End point timeframe
    Baseline (from evening of Study Day -14 to the morning of Study Day 1) through Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    62
    64
    Units: Units on a scale
        least squares mean (standard error)
    -9.177 ( 2.116 )
    -8.273 ( 2.029 )
    No statistical analyses for this end point

    Secondary: Change From Baseline to Week 12 in AO Parameter-Area Under the Reactance Curve (AX)

    Close Top of page
    End point title
    Change From Baseline to Week 12 in AO Parameter-Area Under the Reactance Curve (AX)
    End point description
    Change from baseline to Week 12 in AO Parameter-Area Under the Reactance Curve (AX) is reported. AO is a non-invasive lung function test assessed using an AO device. It is assessed during quiet, tidal breathing with no participant effort required, by superimposing a multi-frequency oscillation onto the participant’s natural breathing. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 12.
    End point type
    Secondary
    End point timeframe
    Baseline (Study Day 1) and Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    64
    66
    Units: kPa/L
        least squares mean (standard error)
    -0.081 ( 0.375 )
    -0.267 ( 0.360 )
    No statistical analyses for this end point

    Secondary: Change From Baseline to Week 12 in Airwave Oscillometry (AO) Parameters

    Close Top of page
    End point title
    Change From Baseline to Week 12 in Airwave Oscillometry (AO) Parameters
    End point description
    Change from baseline to Week 12 in AO parameters including frequency dependence of resistance at 5-20 Hz (R5-R20) and respiratory resistance at 5 Hz (R5; total airway resistance) and 20 Hz (R20; resistance of large airways) is reported. AO is a non-invasive lung function test assessed using an AO device. It is assessed during quiet, tidal breathing with no participant effort required, by superimposing a multi-frequency oscillation onto the participant's natural breathing. AO device uses a vibrating mesh to generate a multifrequency sinusoidal pseudorandom noise (PRN) signal. The AO markers; respiratory resistance at 5 Hz (R5) and 20 Hz (R20) and difference between resistance at 5 and 20Hz (R5-R20; resistance in small airways) are recorded. These markers measure peripheral airway resistance. ITT population: all participants who received any study drug and were analyzed according to received treatment. Number of participants analyzed: participants who were evaluable at Week 12.
    End point type
    Secondary
    End point timeframe
    Baseline (Study Day 1) and Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    64
    66
    Units: kPa*s/L
    least squares mean (standard error)
        R5-R20
    0.008 ( 0.013 )
    -0.014 ( 0.013 )
        R5
    0.015 ( 0.032 )
    -0.030 ( 0.030 )
        R20
    0.006 ( 0.024 )
    -0.017 ( 0.023 )
    No statistical analyses for this end point

    Secondary: Ratio to Baseline in Daily, Night-time, and Awake Time Cough Frequency at Week 12

    Close Top of page
    End point title
    Ratio to Baseline in Daily, Night-time, and Awake Time Cough Frequency at Week 12
    End point description
    Ratio to baseline in daily, night-time, and awake time cough frequency at Week 12 is reported. Objective cough frequency was measured using an ambulatory cough monitoring (ACM) which was fitted and worn by the participants for approximately 24 hours after the visits. Daily cough frequency as full average hourly cough of the full duration of recording, night time cough frequency as sleep average hourly cough of the duration of recording at night, and awake time cough frequency as awake average hourly cough of the full duration of recording minus sleep recording will be derived from the recording. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 12.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -21 to Day -7) and Week 12
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    58
    61
    Units: Ratio to baseline
    geometric mean (confidence interval 80%)
        Daily cough frequency
    0.89 (0.74 to 1.07)
    0.83 (0.70 to 0.99)
        Night time cough frequency
    1.03 (0.62 to 1.70)
    0.61 (0.38 to 0.98)
        Awake time cough frequency
    0.89 (0.74 to 1.07)
    0.84 (0.71 to 0.99)
    No statistical analyses for this end point

    Secondary: Change From Baseline in Pre-BD FEV1 and Post-BD FEV1 Through Week 28 in Participants With Extent of Emphysema < 10%

    Close Top of page
    End point title
    Change From Baseline in Pre-BD FEV1 and Post-BD FEV1 Through Week 28 in Participants With Extent of Emphysema < 10%
    End point description
    Change from baseline in pre-BD FEV1 and post-BD FEV1 through Week 28 in participants with extent of emphysema < 10% is reported. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 28.
    End point type
    Secondary
    End point timeframe
    Baseline (Week -5 to -4) through Week 28 post-dose
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    31
    35
    Units: Litre
    least squares mean (standard error)
        Pre-BD FEV1 (n=31,35)
    0.031 ( 0.057 )
    0.006 ( 0.049 )
        Post-BD FEV1 (n=30,34)
    -0.039 ( 0.071 )
    -0.018 ( 0.059 )
    No statistical analyses for this end point

    Secondary: Change From Baseline in Pre-BD and Post-BD Forced Vital Capacity (FVC) Through Week 28 in Participants With Extent of Emphysema < 10%

    Close Top of page
    End point title
    Change From Baseline in Pre-BD and Post-BD Forced Vital Capacity (FVC) Through Week 28 in Participants With Extent of Emphysema < 10%
    End point description
    Change from baseline in pre-BD and post-BD FVC through Week 28 in participants with extent of emphysema < 10% is reported. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 28.
    End point type
    Secondary
    End point timeframe
    Baseline (Week -5 to -4) through Week 28 post-dose
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    31
    35
    Units: Litre
    least squares mean (standard error)
        Pre-BD FVC (n=31,35)
    -0.143 ( 0.105 )
    -0.056 ( 0.093 )
        Post-BD FVC (n=30,34)
    -0.121 ( 0.114 )
    0.046 ( 0.096 )
    No statistical analyses for this end point

    Secondary: Change From Baseline in Pre-BD FEV1 and Post-BD FEV1 Through Week 28 in Participants With Extent of Emphysema >= 10%

    Close Top of page
    End point title
    Change From Baseline in Pre-BD FEV1 and Post-BD FEV1 Through Week 28 in Participants With Extent of Emphysema >= 10%
    End point description
    Change from baseline in pre-BD FEV1 and post-BD FEV1 through Week 28 in participants with extent of emphysema >= 10% is reported. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 28.
    End point type
    Secondary
    End point timeframe
    Baseline (Week -5 to -4) through Week 28 post-dose
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    29
    29
    Units: Litre
    least squares mean (standard error)
        Pre-BD FEV1
    -0.015 ( 0.036 )
    -0.068 ( 0.034 )
        Post-BD FEV1
    0.074 ( 0.044 )
    -0.053 ( 0.042 )
    No statistical analyses for this end point

    Secondary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)

    Close Top of page
    End point title
    Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
    End point description
    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Adverse event of special interest (AESI) are AEs of scientific and medical interest specific to understanding of tozorakimab and requires close monitoring. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Day 1 through 253 days (maximum observed duration)
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Participants
        Any TEAEs
    53
    50
        Any TESAEs
    14
    9
        Any TEAESIs
    33
    24
    No statistical analyses for this end point

    Secondary: Change From Baseline in Pre-BD and Post-BD FVC Through Week 28 in Participants With Extent of Emphysema >= 10%

    Close Top of page
    End point title
    Change From Baseline in Pre-BD and Post-BD FVC Through Week 28 in Participants With Extent of Emphysema >= 10%
    End point description
    Change from baseline in pre-BD and post-BD FVC through Week 28 in participants with extent of emphysema >= 10% is reported. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 28.
    End point type
    Secondary
    End point timeframe
    Baseline (Week -5 to -4) through Week 28 post-dose
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    29
    29
    Units: Litre
    least squares mean (standard error)
        Pre-BD FVC
    0.089 ( 0.086 )
    -0.121 ( 0.084 )
        Post-BD FVC
    0.081 ( 0.081 )
    -0.094 ( 0.077 )
    No statistical analyses for this end point

    Secondary: Number of Participants With Abnormal Vital Signs Reported as TEAEs

    Close Top of page
    End point title
    Number of Participants With Abnormal Vital Signs Reported as TEAEs
    End point description
    Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (oral or tympanic temperature, diastolic blood pressure, systolic blood pressure, heart [pulse] rate, and respiratory rate). As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Day 1 through 253 days (maximum observed duration)
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Participants
        Hypertension
    2
    3
        Hypotension
    1
    0
        Dyspnoea
    2
    3
        Pyrexia
    1
    0
    No statistical analyses for this end point

    Secondary: Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

    Close Top of page
    End point title
    Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs
    End point description
    Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of clinical chemistry, hematology, endocrinology, and urinalysis. As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Day 1 through 253 days (maximum observed duration)
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Participants
        Anaemia
    0
    1
        Hypercholesterolaemia
    0
    1
        Hyperuricaemia
    0
    1
        Hypertransaminasaemia
    1
    0
        Haematuria
    2
    0
        SARS-CoV-2 test positive
    2
    0
        Hyperthyroidism
    0
    1
        Hypothyroidism
    1
    0
        Urinary tract infection
    0
    1
    No statistical analyses for this end point

    Secondary: Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs

    Close Top of page
    End point title
    Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs
    End point description
    Number of participants with abnormal ECGs reported as TEAEs are reported. As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Day 1 through 253 days (maximum observed duration)
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Participants
        Left ventricular failure
    1
    0
    No statistical analyses for this end point

    Secondary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Level

    Close Top of page
    End point title
    Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Level
    End point description
    Change in NT-proBNP Level from baseline is reported. As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 28.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -35 to Day -28) through Week 28
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    58
    61
    Units: pmol/L
    arithmetic mean (standard deviation)
        Week 28
    4.051 ( 17.937 )
    1.948 ( 14.280 )
    No statistical analyses for this end point

    Secondary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) as Measured by Echocardiogram

    Close Top of page
    End point title
    Change From Baseline in Left Ventricular Ejection Fraction (LVEF) as Measured by Echocardiogram
    End point description
    Change from baseline in LVEF as measured by echocardiogram is reported. As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes those participants who were evaluable at Week 28.
    End point type
    Secondary
    End point timeframe
    Baseline (Week -3 to -1) through Week 28
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Ratio
    arithmetic mean (standard deviation)
        Week 28
    0.9 ( 5.78 )
    0.2 ( 4.61 )
    No statistical analyses for this end point

    Secondary: Number of Participants Seropositive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

    Close Top of page
    End point title
    Number of Participants Seropositive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
    End point description
    Number of participants who were seronegative at baseline and who had positive SARS-Cov-2 serology result at the end of study is reported. As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of participants analyzed (N) denotes the number of participants who were SARS-CoV-2 serum negative at baseline and had at least one post-baseline result.
    End point type
    Secondary
    End point timeframe
    Baseline (Week 0) through Week 28
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    6
    7
    Units: Participants
    6
    6
    No statistical analyses for this end point

    Secondary: Number of Participants With Coronavirus Disease 2019 (COVID-19) Related AEs and SAEs

    Close Top of page
    End point title
    Number of Participants With Coronavirus Disease 2019 (COVID-19) Related AEs and SAEs
    End point description
    The number of participants with COVID-19 related AEs and SAEs are reported. As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    End point type
    Secondary
    End point timeframe
    Day 1 through 253 days (maximum observed duration)
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    67
    68
    Units: Participants
        COVID-19 related AEs
    17
    14
        COVID-19 related SAEs
    1
    0
    No statistical analyses for this end point

    Other pre-specified: Change From Baseline in Post-BD FEV1 To Weeks 12 and 28

    Close Top of page
    End point title
    Change From Baseline in Post-BD FEV1 To Weeks 12 and 28
    End point description
    Change from baseline in post-BD FEV1 to Weeks 12 and 28 is reported. ITT population included all participants who received any study drug and were analyzed according to the treatment they actually received. Here, number of subjects analyzed (N) denotes those participants who were included in the analysis.
    End point type
    Other pre-specified
    End point timeframe
    Baseline (Week -5 to -4) to Weeks 12 and 28 post-dose
    End point values
    Tozorakimab Placebo
    Number of subjects analysed
    65
    67
    Units: Litre
    least squares mean (standard error)
        Week 12
    0.041 ( 0.036 )
    -0.025 ( 0.033 )
        Week 28
    0.021 ( 0.036 )
    -0.049 ( 0.033 )
    Statistical analysis title
    MMRM analysis at Week 28
    Statistical analysis description
    Results are based on the mixed model for repeated measures (MMRM) analysis.
    Comparison groups
    Tozorakimab v Placebo
    Number of subjects included in analysis
    132
    Analysis specification
    Pre-specified
    Analysis type
    superiority [2]
    P-value
    = 0.036 [3]
    Method
    Mixed models analysis
    Parameter type
    Least square mean difference
    Point estimate
    0.07
    Confidence interval
         level
    80%
         sides
    2-sided
         lower limit
    0.02
         upper limit
    0.12
    Notes
    [2] - Kenward-Roger correction has been used for degrees of freedom approximation in the generation of model.
    [3] - One-sided p-value
    Statistical analysis title
    MMRM analysis at Week 12
    Statistical analysis description
    Results are based on the Mixed model for repeated measures (MMRM) analysis.
    Comparison groups
    Tozorakimab v Placebo
    Number of subjects included in analysis
    132
    Analysis specification
    Pre-specified
    Analysis type
    superiority [4]
    P-value
    = 0.044 [5]
    Method
    Mixed models analysis
    Parameter type
    Least square mean difference
    Point estimate
    0.067
    Confidence interval
         level
    80%
         sides
    2-sided
         lower limit
    0.017
         upper limit
    0.116
    Notes
    [4] - Kenward-Roger correction has been used for degrees of freedom approximation in the generation of model.
    [5] - One-sided p-value

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Day 1 through 253 days (maximum observed duration)
    Adverse event reporting additional description
    As-treated population included all participants who received any study drug and were analyzed according to the treatment they actually received.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Participants received 7 doses of SC placebo injection matched to tozorakimab once Q4W.

    Reporting group title
    Tozorakimab
    Reporting group description
    Participants received 7 doses of subcutaneous (SC) tozorakimab Dose Level 1 injection once every 4 weeks (Q4W).

    Serious adverse events
    Placebo Tozorakimab
    Total subjects affected by serious adverse events
         subjects affected / exposed
    9 / 68 (13.24%)
    14 / 67 (20.90%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Bladder cancer
         subjects affected / exposed
    1 / 68 (1.47%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malignant melanoma
         subjects affected / exposed
    1 / 68 (1.47%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Transitional cell carcinoma
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Acetabulum fracture
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wrist fracture
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Transient ischaemic attack
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Pancreatitis
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    6 / 68 (8.82%)
    6 / 67 (8.96%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Osteoarthritis
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Influenza
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia bacterial
         subjects affected / exposed
    1 / 68 (1.47%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia pseudomonal
         subjects affected / exposed
    1 / 68 (1.47%)
    0 / 67 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Covid-19
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    0 / 68 (0.00%)
    1 / 67 (1.49%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo Tozorakimab
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    39 / 68 (57.35%)
    40 / 67 (59.70%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    3 / 68 (4.41%)
    8 / 67 (11.94%)
         occurrences all number
    3
    10
    General disorders and administration site conditions
    Injection site erythema
         subjects affected / exposed
    0 / 68 (0.00%)
    10 / 67 (14.93%)
         occurrences all number
    0
    25
    Respiratory, thoracic and mediastinal disorders
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    27 / 68 (39.71%)
    26 / 67 (38.81%)
         occurrences all number
    56
    53
    Infections and infestations
    Covid-19
         subjects affected / exposed
    14 / 68 (20.59%)
    14 / 67 (20.90%)
         occurrences all number
    14
    15
    Nasopharyngitis
         subjects affected / exposed
    7 / 68 (10.29%)
    3 / 67 (4.48%)
         occurrences all number
    12
    4

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    01 Oct 2020
    Adjustments regarding timing of repeat attempts in case of failure to successfully obtain spontaneous and induced sputum samples. Added text regarding participants who met eligibility criteria for main study but not sub study and clarification regarding quantitative assessment of computerized tomography (CT) scan showing emphysema in Exclusion Criterion 4 (c). Criteria for discontinuation amended. Added detail regarding how the echocardiogram should be performed and urine specific gravity to Table 8 (Laboratory Safety Variables) in protocol. ‘Hepatitis A’ was removed from other safety tests. Intensity Rating Scale was replaced with Severity Rating Scale based on the common terminology criteria for adverse events (CTCAE) criteria.
    08 Feb 2021
    Exploratory induced sputum sub-study and exploratory capnography sub-study were removed, prior to inclusion of any participants in that sub-study. Added PK and immunogenicity samples at study visit (SV) 11. Added exploratory endpoints covering certain spirometry measures. Added instructions on when coronavirus disease 2019 (COVID-19) vaccination should be given to study participants. Added specific study stopping criteria (individual investigational product discontinuation criteria already present). Added clarification for exclusion criterion 15. Removed requirement for surveillance CT scans as exclusion for main study from exclusion criterion 9(g). Added need for future CT scans as exclusion for CT sub-study from exclusion criterion 43. Added clarification for vaccines with adenoviral vectors that are unable to replicate from exclusion criterion 34(d). Added clarification on recording of COVID-19 vaccination. New question added in Appendix J (Example of Patient COVID-19 Screening Questionnaire) for COVID-19 vaccination.
    01 Jun 2021
    Added clarification that pregnancy tests should have been carried out in women of childbearing potential only. Clarified urine pregnancy test at SV2 was not required if CT scan was not performed. Permitted local laboratories to perform severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) nucleic acid testing (nasopharyngeal swab), as well as the central laboratory and permitted less frequent testing dependent on prevalence of COVID-19 infection. In inclusion criterion 3, clarification of influenza and pneumococcal vaccine requirements added. Clarification of a positive interferon gamma release assay (IGRA) test in the context of treated latent tuberculosis (TB) infection added. To remove unnecessary effective prohibition on participants unsuccessfully screened for the Imaging Sub-study being rescreened for the Sub-study. In the case of re-screening, to permit echocardiogram and IGRA (TB test) results no more than 3 months old to be re-used. Included that the randomization schedule may be provided to limited personnel. Clarified information to be recorded in the event of a participant receiving a COVID-19 vaccine. Clarified that agreement to participate in the Study Participant Feedback Questionnaire would be included in the informed consent form (ICF). Congenital abnormality changed to congenital anomaly. Clarification of processing of pharmacokinetic (PK) samples from participants who received placebo. Included that neutralizing antibody may also be assessed.
    23 Jul 2021
    Removed Exclusion Criterion 4 (predominant emphysema). Section 2.2 (Background), Section 2.3.1 (Risk Assessment) and Section 5.2 (Scientific rationale for study design) updated with new emerging evidence and rationale for update. Added additional secondary and exploratory objective to assess response to tozorakimab by extent of emphysema on baseline CT scan. Reference to exclusion criteria for extent of emphysema removed. Added emphysema subgroup analysis for primary endpoint. Polymerase chain reaction (PCR) analysis changed to nucleic acid analysis. Added information that automated calculation of emphysema percentage was not possible. Changed timing of inclusion criterion 9 from >= 1 exacerbation of chronic obstructive pulmonary disease (COPD) in 12 months to >= 1 exacerbation in 24 months and updated rationale for study population to reflect this change. Changed BMI to 18-35 kg/m^2. Clarified wording on lung resection exclusion and testing. Clarification on testing for hepatitis C infection added.
    16 Feb 2022
    Amended participants randomization and number of evaluable participants. Updated new participant numbers, sample size justification in statistical method section. Clarified spirometry assessment timing. Added salivary sample as additional option for SARS-CoV-2 nucleic acid test. Updated risk assessment related to progression of heart failure. Revised CT risk mitigations. Removed Week 20 assessment of blood biomarkers and assessment of soluble receptor for advanced glycation end products (sRAGE) and fibronectin. mRNA nasal transcriptome exploratory biomarkers clarified as from nasal mucosal sampling. Week 36 assessment of serum biomarkers added. Updated number of participants to be randomized and expected percentage of participants in baseline and inhaled corticosteroids (ICS) strata removed. Added advice on ensuring adequate time for CT and echocardiogram assessments. Clarified use of eDiary and spirometry assessment timing. Reduced overall number of participants in the CT sub-study. Clarified when to perform echocardiogram in cases of suspected heart failure. Updated inclusion criterion 1, 3, 4, 5, 8, 9, 13, and exclusion criterions 1, 3a, 3c, 3e, 3f, 5, 9g, 24, 9e, 10, 15, 23, 34h, 34i, 34k, 41, and 43. Removed collection of spontaneous sputum samples from home. Phenotype monitoring details of participants removed. Reduced overall number of participants in CT sub-study to remain proportionate to reduced size of main study. Text around strata caps and safety alerts removed. Revised vaccination against influenza and pneumonia advice. Added baseline audiometry testing to be documented before randomization. Advice on spirometry assessment timing clarified. Dose of radiation in mSV removed. Revised text to add circumstances in which anti-drug antibody (ADA) samples could be collected after follow-up period. Reduced size of population in small CT exploratory sub-study to explore impact of tozorakimab on radiological biomarkers of airways inflammation and mucus plugging.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:17:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA